Interestingly, all four patients who had modest tumor regression had pathogenic frameshift mutations in SETD2, compared with nonsense, missense, or splice site mutations, along with a trend toward longer treatment duration with frameshift mutations. The gene discussed is SETD2; the disease is neoplasm.